259 related articles for article (PubMed ID: 33562780)
1. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
3. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
4. CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition.
Rosales M; Rodríguez-Ulloa A; Pérez GV; Besada V; Soto T; Ramos Y; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Front Mol Biosci; 2022; 9():834814. PubMed ID: 35359604
[TBL] [Abstract][Full Text] [Related]
5. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Klink M; Rahman MA; Song C; Dhanyamraju PK; Ehudin M; Ding Y; Steffens S; Bhadauria P; Iyer S; Aliaga C; Desai D; Huang S; Claxton D; Sharma A; Gowda C
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807974
[TBL] [Abstract][Full Text] [Related]
7. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
8. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
9. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J
FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879
[TBL] [Abstract][Full Text] [Related]
10. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
11. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
15. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.
Vázquez-Blomquist D; Ramón AC; Rosales M; Pérez GV; Rosales A; Palenzuela D; Perera Y; Perea SE
BMC Genomics; 2023 Jul; 24(1):373. PubMed ID: 37400761
[TBL] [Abstract][Full Text] [Related]
17. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
[TBL] [Abstract][Full Text] [Related]
18. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
19. CK2 inhibition protects white matter from ischemic injury.
Baltan S; Bastian C; Quinn J; Aquila D; McCray A; Brunet S
Neurosci Lett; 2018 Nov; 687():37-42. PubMed ID: 30125643
[TBL] [Abstract][Full Text] [Related]
20. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D
Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
